You are here
Biomarker Predicts Worse Outcome in CML
2em; font-weight: bold; ">
Biomarker Predicts Worse Outcome in Chronic Myeloid Leukemia
Elsevier Global Medical News. 2011 Jun 23, S Freeman
LONDON (EGMN) - Measuring levels of a newly described protein at diagnosis could help identify patients that are going to fare worse than others with chronic myeloid leukemia, data from a small study suggest.
Cancerous inhibitor of protein phosphatase 2A (CIP2A) levels were found to be significantly higher in patients with chronic myeloid leukemia (CML) who later went into blast crisis, reported researchers from the University of Liverpool (England). CIP2A could, therefore, represent a novel drug target as well as a biomarker for the disease.
more.....
http://oncologystat.com/news/Biomarker_Predicts_Worse_Outcome_in_Chronic_Myeloid_Leukemia_